VBL Therapeutics to Present Anti-Inflammatory Properties of VBL-201 at Keystone Symposium

TEL AVIV, Israel–(Business Wire)–
VBL Therapeutics, a clinical-stage biotechnology company committed to the
development of novel treatments for immune-inflammatory diseases and cancer,
today announced that the company will present preclinical data from its lead
program, VB-201, at the Keystone Symposium on Bioactive Lipids: Biochemistry and
Diseases. Eyal Breitbart, Ph.D., vice president, research at VBL is scheduled to
present a poster entitled “Lecinoxoids – Novel Anti-inflammatory Oxidized
Phospholipids” on Monday, June 7, 2010 at 12:30 p.m. JST in Kyoto, Japan.

The Keystone Symposium on Bioactive Lipids: Biochemistry and Diseases is a forum
for scientists to share their progress in lipid mediators and the translation
from model systems to an understanding of their role in human physiology,
disease and drug action. Keystone Symposia are recognized as catalysts for
advancing biomedical and life sciences by connecting scientists within and
across disciplines in an environment conducive to information exchange, the
generation of new ideas, and acceleration of applications that benefit society.

VB-201 is the first in a new class of drugs and the lead candidate of several
proprietary phospholipid analogs from VBL`s proprietary Lecinoxoid family that
were designed to be orally available, anti-inflammatory medicines. VB-201 has
successfully completed four Phase 1 clinical trials involving 120 healthy
subjects under a U.S. investigational new drug (IND) application. These Phase 1
trials demonstrated that VB-201 was well tolerated with a favorable safety
profile. Preclinical studies indicate that VB-201 has significant potential to
treat inflammation in chronic diseases such as psoriasis, rheumatoid arthritis,
multiple sclerosis, inflammatory bowel disease, and also found to bring about
regression of atherosclerosis. VB-201 is currently being evaluated in a Phase 2
efficacy and safety study for the treatment of patients with psoriasis.

About VBL Therapeutics

VBL Therapeutics is an innovative, clinical-stage biotechnology company
committed to the development of novel treatments for immune-inflammatory
diseases and cancer. VBL has pioneered the Lecinoxoid class of oral
anti-inflammatory agents and VB-201 is the lead candidate from this program,
which has entered Phase 2 clinical development in patients with psoriasis. In
addition, VBL has a proprietary Vascular Targeting System (VTS) technology
platform that has yielded VB-111, the first dual-action, anti-angiogenic and
vascular disruptive agent (VDA) for cancer, which is expected to enter Phase 2
clinical trials in 2010. The company was founded in 2000 and is based in Tel
Aviv, Israel. VBL has more than 60 granted patents and more than 115 patents
pending. For more information on the company, please visit www.vblrx.com.

Pure Communications
Dan Budwick, 973-271-6085

Copyright Business Wire 2010

VBL Therapeutics to Present Anti-Inflammatory Properties of VBL-201 at Keystone Symposium

TEL AVIV, Israel–(Business Wire)–
VBL Therapeutics, a clinical-stage biotechnology company committed to the
development of novel treatments for immune-inflammatory diseases and cancer,
today announced that the company will present preclinical data from its lead
program, VB-201, at the Keystone Symposium on Bioactive Lipids: Biochemistry and
Diseases. Eyal Breitbart, Ph.D., vice president, research at VBL is scheduled to
present a poster entitled “Lecinoxoids – Novel Anti-inflammatory Oxidized
Phospholipids” on Monday, June 7, 2010 at 12:30 p.m. JST in Kyoto, Japan.

The Keystone Symposium on Bioactive Lipids: Biochemistry and Diseases is a forum
for scientists to share their progress in lipid mediators and the translation
from model systems to an understanding of their role in human physiology,
disease and drug action. Keystone Symposia are recognized as catalysts for
advancing biomedical and life sciences by connecting scientists within and
across disciplines in an environment conducive to information exchange, the
generation of new ideas, and acceleration of applications that benefit society.

VB-201 is the first in a new class of drugs and the lead candidate of several
proprietary phospholipid analogs from VBL`s proprietary Lecinoxoid family that
were designed to be orally available, anti-inflammatory medicines. VB-201 has
successfully completed four Phase 1 clinical trials involving 120 healthy
subjects under a U.S. investigational new drug (IND) application. These Phase 1
trials demonstrated that VB-201 was well tolerated with a favorable safety
profile. Preclinical studies indicate that VB-201 has significant potential to
treat inflammation in chronic diseases such as psoriasis, rheumatoid arthritis,
multiple sclerosis, inflammatory bowel disease, and also found to bring about
regression of atherosclerosis. VB-201 is currently being evaluated in a Phase 2
efficacy and safety study for the treatment of patients with psoriasis.

About VBL Therapeutics

VBL Therapeutics is an innovative, clinical-stage biotechnology company
committed to the development of novel treatments for immune-inflammatory
diseases and cancer. VBL has pioneered the Lecinoxoid class of oral
anti-inflammatory agents and VB-201 is the lead candidate from this program,
which has entered Phase 2 clinical development in patients with psoriasis. In
addition, VBL has a proprietary Vascular Targeting System (VTS) technology
platform that has yielded VB-111, the first dual-action, anti-angiogenic and
vascular disruptive agent (VDA) for cancer, which is expected to enter Phase 2
clinical trials in 2010. The company was founded in 2000 and is based in Tel
Aviv, Israel. VBL has more than 60 granted patents and more than 115 patents
pending. For more information on the company, please visit www.vblrx.com.

Pure Communications
Dan Budwick, 973-271-6085

Copyright Business Wire 2010

Indian-origin researcher virtually builds Rome in a day!

Washington, September 16 (ANI): The ancient city of Rome can now be virtually built within a matter of hours, thanks to a new computer algorithm developed by an Indian-origin University of Washington researcher.

The new program can digitise hundreds of pictures of the city, including the Colosseum and St. Peter’s Basilica, in just a matter of hours.

It uses hundreds of thousands of tourist photos to automatically reconstruct an entire city in about a day.

The tool is the most recent in a series developed at the UW to harness the increasingly large digital photo collections available on photo-sharing Web sites.

The university researchers behind this innovation have even built a digital Rome from 150,000 tourist photos, tagged with the word “Rome” or “Roma” that were downloaded from the popular photo-sharing Web site, Flickr.

Computers analysed each image, combined them in 21 hours, and created a 3-D digital model.

The model can help one fly around Rome’s landmarks, from the Trevi Fountain to the Pantheon to the inside of the Sistine Chapel.

“How to match these massive collections of images to each other was a challenge,” said Sameer Agarwal, a UW acting assistant professor of computer science and engineering, and lead author of a paper being presented in October at the International Conference on Computer Vision in Kyoto, Japan.

He said: “(Until now) even if we had all the hardware we could get our hands on and then some, a reconstruction using this many photos would take forever.”

In addition to Rome, the researchers have recreated the Croatian coastal city of Dubrovnik, processing 60,000 images in less than 23 hours using a cluster of 350 computers, and Venice, Italy, processing 250,000 images in 65 hours using a cluster of 500 computers.

The novel technique can create online maps that offer viewers a virtual-reality experience.

The software can even build cities for video games automatically, and may also be used in architecture for digital preservation of cities, or integrated with online maps.

The research was supported by the National Science Foundation, the Office of Naval Research and its Spawar lab, Microsoft Research, and Google. (ANI)

Japan power firms make scant progress with CO2 cuts

TOKYO, April 10 (Reuters) – Japan’s electric power companies made little progress in producing low-carbon electricity and lowering emissions in the past year, industry data showed on Friday, mostly due to an outage at a nuclear power plant.

The data increases the likelihood that Japanese power firms, factories and companies will have to buy more carbon offsets from abroad to help Japan to meet its commitments under the Kyoto Protocol.

Japan’s commitments depend largely on the electric power sector’s efforts to make electricity low carbon by using more non-fossil fuels and producing 20 percent less carbon dioxide emissions per kilowatt hour than 1990/1991 levels.

Japan’s 12 electric power companies produced 0.45 kg CO2 per kilowatt hour in the year to March 2008, preliminary data by the Federation of Electric Power Companies showed.

That compares with 0.453 kg a year ago, against the sector’s target of 0.34 kg over the five years to March 2013 from 0.417 kg in 1990/1991.

Tokyo Electric Power Co’s (9501.T) 1,356-megawatt No.7 reactor at its Kashiwazaki-Kariwa nuclear plant, the world’s largest, has been closed since July 2007 after a powerful earthquake. [ID:nT327041]

The industry data is being closely watched. 2008/2009 was the start of Japan’s five-year plan under the Kyoto Protocol, the U.N.-led global climate pact under which many nations aim to reduce emissions.

The electric power sector’s CO2 emissions per kilowatt hour is used as a basis to calculate emissions at offices and factories from their power consumption. [ID:nT299251]

The sector’s voluntary target is not legally binding, but it considers it a commitment and has said it would make up any shortfall with U.N. approved emission credits from abroad or other offsets. (Editing by Sue Thomas)

Soon, anti-ulcer yoghurt

Washington, Mar 23 (ANI): A new type of yoghurt has been found to be effective against bacteria that cause stomach ulcers, according to a new study.

A type of bacteria called Helicobacter pylori (H. pylori) or over-use of aspirin and or other nonsteroidal antiinflammatory drugs causes most stomach ulcers.

During the study, the research team led by Dr. Hajime Hatta, a chemist at Kyoto Women’s University in Kyoto, Japan, found that H. pylori seems to rely on a protein called urease to attach to and infect the stomach lining.

The team suggested that drinking yogurt fortified with urease antibody could help ward off stomach ulcers.

During the study, the researchers injected chickens with urease, and allowed their immune systems to produce an antibody to the protein.

The team then harvested the antibody, called IgY-urease, from chicken eggs.

Hatta and colleagues theorized that yogurt containing the antibody might help prevent the bacteria from adhering to the stomach lining.

The team later recruited 42 people infected with H. pylori, who were asked to consume cups daily of either plain yogurt or yogurt containing the antibody for four weeks.

They found that levels of urea, a byproduct of urease, decreased significantly in the antibody group when compared with the control group, indicating reduced bacterial activity.

“The results indicate that the suppression of H. pylori infection in humans could be achieved by drinking yogurt fortified with urease antibody,” Hatta said.

The antibody was eventually destroyed by stomach acid, but not before having its beneficial effect.

Hatta said although the yogurt appears less effective than antibiotics for reducing levels of H. pylori, it is a lot easier to take than medicine and can be eaten daily as part of regular dietary routine.

The study was presented at the 237th National Meeting of the American Chemical Society. (ANI)

Shedding light on evolution of stone-tool use in early hominids

Washington, Jan 13 (ANI): In a new research, scientists have studied stone-handling behavior in several troops of Japanese macaques, which may shed light on the evolution of stone-tool use in early hominids.

By watching these monkeys acquire and maintain behavioral traditions from generation to generation, the scientists have gained insight into the cultural evolution of humans.

Primatologists Michael A. Huffman, Charmalie A.D. Nahallage, and Jean-Baptiste Leca from the Primate Research Institute in Kyoto, Japan, assessed social learning exhibited by these macaques during stone-handling, a behavior that has been passed down from elder to younger since it was observed in some of the troops in 1979.

Stone-handling, in this study, included rubbing and clacking stones together, pounding them onto hard surfaces, picking them up, and cuddling, carrying, pushing, rolling and throwing them.

The scientists found, for example, that an infant’s proximity to their mother had a significant impact on the development of the infant’s stone-handling abilities.

In other words, infants with mothers who frequently exhibited stone-handling behaviors spent more time with their mother, about 75 percent of their time, during the first three months of life, and they also participated in stone-handling earlier in life than the other infants.

These findings suggest that the mothers’ frequent stone-handling caught the infants’ attention, and as a result, the infants acquired the behavior more quickly than other infants.

Furthermore, the primatologists reported that the stone-handling behavior changed with each generation as individual macaques contributed their own patterns of stone-handling, such as stone-throwing.

According to the authors, “The recent emergence of a unique behavior, stone-throwing, may serve to augment the effect of intimidation displays.”

“Research on such transformation may shed light on the evolution of stone-tool use in early hominids,” they concluded. (ANI)